Herman T S, Jones S E
Cancer. 1978 Oct;42(4):1976-82. doi: 10.1002/1097-0142(197810)42:4<1976::aid-cncr2820420442>3.0.co;2-n.
Eighty-two patients with advanced Hodgkin's disease who were in apparent complete remission (CR) after receiving 10 courses of combination chemotherapy were systematically reevaluated for persisting disease. Occult Hodgkin's disease was found in 10 (12%) of these patients and was predominantly present in nodal sites (91%) which were known to have been involved at initial staging (100%). Repeat chest radiography, Gallium-67 tumor scanning and lymphography were the most helpful procedures for detecting residual disease. Nine of the 72 (13%) patients felt to be free of disease after negative restaging subsequently relapsed within 8 months. Sites of early relapse, like the sites of disease found at restaging, occurred almost always in previously involved nodal areas. We conclude that systematic restaging should be incorporated into subsequent lymphoma trials in order to define more clearly complete remission and that every patient treated for lymphoma should undergo a careful restaging evaluation before therapy is discontinued.
82例晚期霍奇金病患者在接受10个疗程的联合化疗后看似完全缓解（CR），对其持续存在的疾病进行了系统的重新评估。在这些患者中有10例（12%）发现了隐匿性霍奇金病，主要存在于已知在初始分期时受累的淋巴结部位（91%）（100%）。重复胸部X线摄影、镓-67肿瘤扫描和淋巴管造影是检测残留疾病最有用的检查方法。72例（13%）经再次分期后被认为无疾病的患者中有9例在8个月内复发。早期复发部位与再次分期时发现的疾病部位一样，几乎总是出现在先前受累的淋巴结区域。我们得出结论，应将系统的再次分期纳入后续淋巴瘤试验，以便更明确地界定完全缓解，并且每例接受淋巴瘤治疗的患者在停止治疗前都应接受仔细的再次分期评估。
